These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26338913)

  • 21. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging.
    Warmuth C; Gunther M; Zimmer C
    Radiology; 2003 Aug; 228(2):523-32. PubMed ID: 12819338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results.
    Shin JH; Lee HK; Kwun BD; Kim JS; Kang W; Choi CG; Suh DC
    AJR Am J Roentgenol; 2002 Sep; 179(3):783-9. PubMed ID: 12185064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging.
    Joo I; Lee JM; Grimm R; Han JK; Choi BI
    Radiology; 2016 Jan; 278(1):104-13. PubMed ID: 26200601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas.
    Arevalo-Perez J; Peck KK; Young RJ; Holodny AI; Karimi S; Lyo JK
    J Neuroimaging; 2015; 25(5):792-8. PubMed ID: 25867683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCE-MRI in Human Gliomas: A Surrogate for Assessment of Invasive Hypoxia Marker HIF-1Α Based on MRI-Neuronavigation Stereotactic Biopsies.
    Xie Q; Wu J; Du Z; Di N; Yan R; Pang H; Jin T; Zhang H; Wu Y; Zhang Y; Yao Z; Feng X
    Acad Radiol; 2019 Feb; 26(2):179-187. PubMed ID: 29754996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using intraoperative dynamic contrast-enhanced T1-weighted MRI to identify residual tumor in glioblastoma surgery.
    Özduman K; Yıldız E; Dinçer A; Sav A; Pamir MN
    J Neurosurg; 2014 Jan; 120(1):60-6. PubMed ID: 24138206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
    Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
    Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors.
    Arisawa A; Watanabe Y; Tanaka H; Takahashi H; Matsuo C; Fujiwara T; Fujiwara M; Fujimoto Y; Tomiyama N
    Neuroradiology; 2018 Jun; 60(6):599-608. PubMed ID: 29705876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade.
    Vajapeyam S; Brown D; Johnston PR; Ricci KI; Kieran MW; Lidov HGW; Poussaint TY
    AJNR Am J Neuroradiol; 2018 Mar; 39(3):552-557. PubMed ID: 29301780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
    Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
    Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
    Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
    J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.